Electromagnetic fields (EMF) are increasing in popularity as a safe and non-invasive therapy. On the one hand, it is widely acknowledged that EMF can regulate the proliferation and differentiation of stem cells, promoting the undifferentiated cells capable of osteogenesis, angiogenesis, and chondroblast differentiation to achieve bone repair purpose. On the other hand, EMF can inhibit tumor stem cells proliferation and promote apoptosis to suppress tumor growth. As an essential second messenger, intracellular calcium plays a role in regulating cell cycle, such as proliferation, differentiation and apoptosis. There is increasing evidence that the modulation of intracellular calcium ion by EMF leads to differential outcomes in different stem cells. This review summarizes the regulation of channels, transporters, and ion pumps by EMF-induced calcium oscillations. It furtherly discusses the role of molecules and pathways activated by EMF-dependent calcium oscillations in promoting bone and cartilage repair and inhibiting tumor stem cells growth.
Bone tissue engineering (BTE) emerged as one of the exceptional means for bone defects owing to it providing mechanical supports to guide bone tissue regeneration. Great advances have been made to facilitate the success of BTE in regenerating bone within defects. The use of externally applied fields has been regarded as an alternative strategy for BTE. Electromagnetic fields (EMFs), known as a simple and non-invasive therapy, can remotely provide electric and magnetic stimulation to cells and biomaterials, thus applying EMFs to assist BTE would be a promising strategy for bone regeneration. When combined with BTE, EMFs improve cell adhesion to the material surface by promoting protein adsorption. Additionally, EMFs have positive effects on mesenchymal stem cells and show capabilities of pro-angiogenesis and macrophage polarization manipulation. These advantages of EMFs indicate that it is perfectly suitable for representing the adjuvant treatment of BTE. We also summarize studies concerning combinations of EMFs and diverse biomaterial types. The strategy of combining EMFs and BTE receives encouraging outcomes and holds a promising future for effectively treating bone defects.
The chronic articular disease osteoarthritis (OA) is characterized by osteophyte generation, subchondral bone remodeling, and cartilage deterioration. Low levels of H2S catalyzed by cystathionine-γ-lyase (CSE) encoded by Cthhas neuroprotective, cardioprotective, anti-apoptotic, and anti-inflammatory effects thus, Cth is being developed as a potential therapy for the management of the pathogenesis and symptoms of osteoarthritis. Single-cell RNA sequencing (scRNA-seq) and immunohistochemistry of human cartilage revealed that the expression of CTH was decreased in OA patients. We found that Cthoverexpression decrease IL-1β-induced overactivation of the NF-κB signaling pathway. In vivo, Cthoverexpression relieved pain response and cartilage damage in the anterior cruciate ligament transection (ACLT) rat model. In vitro, CSE alleviated chondrocytes catabolism, inflammation, apoptosis, and senescence, and suppressed the NF-κB pathway. We postulate that CSE has therapeutic effects in suppressing inflammation and degeneration in OA and should be further investigated clinically.
31 January 2026 in Advanced Composites and Hybrid Materials
Osteoarthritis (OA) is a chronic joint disorder characterized by synovial inflammation, cartilage degradation and macrophage polarization imbalance, where excessive reactive oxygen species (ROS) accumulation and mitochondrial dysfunction exacerbate pro-inflammatory M1 macrophage polarization. Here, a pH-responsive nanocomposite (Se/LDH@PEG-M) is developed by integrating selenium (Se) within MgAl-layered double hydroxide (MgAl-LDH), modified with PEGylation and loaded with the mitochondria-targeted antioxidant Mito-TEMPO. The synthesized nanocomposite retains glutathione peroxidase (GPX)-like activity and the antioxidant capacity of Se nanoparticles, while exhibiting pH-responsive degradation to neutralize acidic OA microenvironments and release Mg²⁺, Se and Mito-TEMPO for inflammation suppression, ROS scavenging and macrophage polarization modulation. In vitro, Se/LDH@PEG-M effectively inhibits pro-inflammatory M1 polarization while promoting anti-inflammatory M2 phenotypes by suppressing multiple inflammatory pathways, restoring redox homeostasis, and enhancing mitochondrial oxidative phosphorylation and ATP production via respiratory chain activation. Conditioned medium from Se/LDH@PEG-M-treated macrophages attenuates chondrocyte apoptosis, inflammation and catabolism compared to LPS group. In murine OA models, intra-articular Se/LDH@PEG-M administration effectively alleviates synovial inflammation, suppresses osteophyte formation and mitigates cartilage degradation. This multifunctional nanocomposite concurrently targets OA pathogenesis through macrophage immunomodulation, ROS scavenging and mitochondrial protection, providing a potential therapeutic strategy for OA management. Graphical Abstract Schematic illustration of the synthesis process and therapeutic mechanism of Se/LDH@PEG-M. (A)The synthesis procedure of Se/LDH@PEG-M nanocomposites. The nanocomposites were developed by integrating selenium (Se) into Mg-Al layered double hydroxides, followed by PEG modification and loading with mitochondria-targeted antioxidant Mito-TEMPO. (B) The therapeutic mechanism of Se/LDH@PEG-M. The nanocomposites degraded in acidic OA microenvironments and releasing Mg²⁺, Se and Mito-TEMPO for inflammation suppression, ROS scavenging and immunomodulation.
Electromagnetic fields (EMFs) have emerged as an effective treatment for osteoporosis. However, the specific mechanism underlying their therapeutic efficacy remains controversial. Herein, we confirm the pro-osteogenic effects of 15 Hz and 0.4-1 mT low-frequency sinusoidal EMFs (SEMFs) on rat bone marrow mesenchymal stem cells (BMSCs). Subsequent miRNA sequencing reveal that miR-34b-5p is downregulated in both the 0.4 mT and 1 mT SEMFs-stimulated groups. To clarify the role of miR-34b-5p in osteogenesis, BMSCs are transfected separately with miR-34b-5p mimic and inhibitor. The results indicate that miR-34b-5p mimic transfection suppress osteogenic differentiation, whereas inhibition of miR-34b-5p promote osteogenic differentiation of BMSCs. In vivo assessments using microcomputed tomography, H&E staining, and Masson staining show that miR-34b-5p inhibitor injections alleviate bone mass loss and trabecular microstructure deterioration in ovariectomy (OVX) rats. Further validation demonstrates that miR-34b-5p exerts its effects by regulating STAC2 expression. Modulating the miR-34b-5p/STAC2 axis attenuate the pro-osteogenic effects of low-frequency SEMFs on BMSCs. These studies indicate that the pro-osteogenic effect of SEMFs is partly due to the regulation of the miR-34b-5p/STAC2 pathway, which provides a potential therapeutic candidate for osteoporosis.
Objectives: Osteoarthritis (OA) is a leading cause of chronic pain and disability worldwide, traditionally viewed as a disease of aging. However, emerging evidence highlights its increasing prevalence among middle-aged adults (40–59 years), a population critical to socioeconomic stability. This study is designed to assess the burden of OA among middle-aged adults. Methods: Data were sourced from the Global Burden of Disease study (GBD) 2021. Incidence, prevalence and years lived with disability (YLDs) of OA were calculated in middle-aged adults from 1990 to 2021. Variability in OA burden was examined by sociodemographic index (SDI) and geographical region. Incidence was forecast to 2050 using the GBD Foresight Visualization tool. Results: Incident cases of OA among middle-aged adults increased by 123.7%, from 11.8 million in 1990 to 26.4 million in 2021. Approximately 56.5% of incident cases and 37.9% of prevalent cases occur within middle-aged group, underscoring its critical burden. The middle-aged population experienced 70% and 331% higher incident cases compared with elderly population (>60 years) and younger population (30–39 years), respectively. The highest number of YLDs was observed in the high-income region. A significant positive association was found between OA burden and SDI. By 2050, the age-standardized incident rate of OA in middle-aged population is projected to increase by 10.2%, with hand OA showing the largest rise. Conclusion: This study underscores the growing burden of OA among middle-aged adults, a population that has been historically underrepresented in OA research. The findings highlight the urgent need to prioritize prevention strategies. Early intervention could significantly delay disease progression and alleviate the future burden.